The orphan nuclear receptor Nurr1 agonist amodiaquine mediates neuroprotective effects in 6-OHDA Parkinson’s disease animal model by enhancing the phosphorylation of P38 mitogen-activated kinase but not PI3K/AKT signaling pathway
- 28 January 2021
- journal article
- research article
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 36 (4) , 609-625
Abstract
Recent studies implicate the defects or altered expression of the orphan nuclear receptor Nurr1 gene in the substantia nigra in Parkinson’s disease pathogenesis. In an attempt to corroborate the treatment-modifying disease that would replicate the effect of Nurr1, it has been found that amodiaquine and Nurr1 had the same chemical scaffolding, indicating a crucial structure-activity relationship. Interestingly, amodiaquine stimulate the transcriptional function of Nurr1 by physical interaction with its ligand-binding domain (LBD). However, the signaling route by which Nurr1 is activated by amodiaquine to cause the protective effect remains to be elucidated. We first demonstrated that amodiaquine treatment ameliorated behavioural deficits in 6-OHDA Parkinson’s disease mouse model, and it promoted dopaminergic neurons protection signified by Tyrosine hydroxylase (TH) and dopamine transporter (DAT) mRNA; Tyrosine hydroxylase (TH) protein expression level and the immunoreactivity in the substantia nigra compacta. Subsequently, we used inhibitors to ascertain the effect of amodiaquine on Akt and P38 Mapk as crucial signaling pathways for neuroprotection. Wortmannin (Akt Inhibitor) induced a significant reduction of Akt mRNA; however, there was no statistical difference between the amodiaquine-treated group and the control group suggesting that amodiaquine may not be the active stimulant of Akt. Western blot analysis confirmed that the phosphorylated Akt decreased significantly in the amodiaquine group compared to the control group. In the same vein, we found that amodiaquine substantially increased the level of phosphorylated P38 Mapk. When P38 Mapk inhibited by SB203580 (P38-Mapk Inhibitor), the total P38 Mapk but not the phosphorylated P38 Mapk decreased significantly, while tyrosine hydroxylase significantly increased. These results collectively suggest that amodiaquine can augment tyrosine hydroxylase expression via phosphorylated P38 Mapk while negatively regulating the phosphorylated Akt in protein expression.Keywords
Funding Information
- National Natural Science Foundation of China (81971006)
This publication has 65 references indexed in Scilit:
- Murine Model for Parkinson's Disease: from 6-OH Dopamine Lesion to Behavioral TestJournal of Visualized Experiments, 2010
- Regulation of the postnatal development of dopamine neurons of the substantia nigra in vivo by Akt/protein kinase BJournal of Neurochemistry, 2009
- RTP801 Is Induced in Parkinson's Disease and Mediates Neuron Death by Inhibiting Akt Phosphorylation/ActivationJournal of Neuroscience, 2008
- The life of a cell: apoptosis regulation by the PI3K/PKB pathwayBiochemical Journal, 2008
- Activation of p38MAPK Contributes to Expanded Polyglutamine-Induced CytotoxicityPLOS ONE, 2008
- Role of PI3-K/Akt pathway and its effect on glial cell line-derived neurotrophic factor in midbrain dopamine cellsActa Pharmacologica Sinica, 2007
- Age-dependent dopaminergic dysfunction in Nurr1 knockout miceExperimental Neurology, 2005
- Age‐related decreases in Nurr1 immunoreactivity in the human substantia nigraJournal of Comparative Neurology, 2002
- Role of PI 3-kinase, Akt and Bcl-2–related proteins in sustaining the survival of neurotrophic factor–independent adult sympathetic neuronsJournal of Cell Biology, 2001
- Pyridinylimidazole Compound SB 203580 Inhibits the Activity but Not the Activation of p38 Mitogen-Activated Protein KinaseBiochemical and Biophysical Research Communications, 1999